Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer

Yingjia Ni; Keon R. Schmidt; Barnes A. Werner; Jenna K. Koenig; Ian H. Guldner; Patricia M. Schnepp; Xuejuan Tan; Lan Jiang; Misha Host; Longhua Sun; Erin N. Howe; Junmin Wu; Laurie E. Littlepage; Harikrishna Nakshatri; Siyuan Zhang

doi:10.1038/s41467-019-10743-7

Nature Communications (Jun 2019)

Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer

Yingjia Ni,
Keon R. Schmidt,
Barnes A. Werner,
Jenna K. Koenig,
Ian H. Guldner,
Patricia M. Schnepp,
Xuejuan Tan,
Lan Jiang,
Misha Host,
Longhua Sun,
Erin N. Howe,
Junmin Wu,
Laurie E. Littlepage,
Harikrishna Nakshatri,
Siyuan Zhang

Affiliations

Yingjia Ni: Department of Biological Sciences, College of Science, University of Notre Dame
Keon R. Schmidt: Department of Biological Sciences, College of Science, University of Notre Dame
Barnes A. Werner: Department of Biological Sciences, College of Science, University of Notre Dame
Jenna K. Koenig: Department of Biological Sciences, College of Science, University of Notre Dame
Ian H. Guldner: Department of Biological Sciences, College of Science, University of Notre Dame
Patricia M. Schnepp: Department of Biological Sciences, College of Science, University of Notre Dame
Xuejuan Tan: Department of Biological Sciences, College of Science, University of Notre Dame
Lan Jiang: Department of Biological Sciences, College of Science, University of Notre Dame
Misha Host: Department of Biological Sciences, College of Science, University of Notre Dame
Longhua Sun: Department of Biological Sciences, College of Science, University of Notre Dame
Erin N. Howe: Department of Biological Sciences, College of Science, University of Notre Dame
Junmin Wu: Mike and Josie Harper Cancer Research Institute, University of Notre Dame
Laurie E. Littlepage: Mike and Josie Harper Cancer Research Institute, University of Notre Dame
Harikrishna Nakshatri: Indiana University Melvin and Bren Simon Cancer Center
Siyuan Zhang: Department of Biological Sciences, College of Science, University of Notre Dame

DOI: https://doi.org/10.1038/s41467-019-10743-7
Journal volume & issue: Vol. 10, no. 1
pp. 1 – 15

Abstract

Read online

The use of of CDK4/6 inhibitors to treat patients with TNBC is limited by loss of Rb. Here, the authors show that a combination of CDK4/6 inhibitor and EGFR inhibitor is effective against DEDD-overexpressing TNBC, independent of Rb status.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal